Immunogenicity and Safety of the 13-Valent Pneumococcal Conjugate Vaccine versus the 23-Valent Polysaccharide Vaccine in Unvaccinated HIV-Infected Adults: A Pilot, Prospective Controlled Study

被引:21
作者
Lombardi, Francesca [1 ]
Belmonti, Simone [1 ]
Fabbiani, Massimiliano [1 ,4 ]
Morandi, Matteo [2 ]
Rossetti, Barbara [3 ]
Tordini, Giacinta [2 ]
Cauda, Roberto [1 ]
De Luca, Andrea [2 ,3 ]
Di Giambenedetto, Simona [1 ]
Montagnani, Francesca [2 ,3 ]
机构
[1] Univ Cattolica Sacro Cuore, Inst Clin Infect Dis, Largo Agostino Gemelli 8, I-00168 Rome, Italy
[2] Univ Siena, Dept Med Biotechnol, Viale Bracci 16, Siena, Italy
[3] Hosp Dept Specialized & Internal Med, Univ Div Infect Dis, Viale Bracci 16, Siena, Italy
[4] Univ Milano Bicocca, San Gerardo Hosp, Dept Internal Med, Div Infect Dis, Monza, Italy
关键词
ACTIVE ANTIRETROVIRAL THERAPY; IMMUNODEFICIENCY-VIRUS-INFECTION; SEROLOGICAL RESPONSE; ANTIBODY-RESPONSES; RANDOMIZED-TRIAL; DISEASE; CHILDREN; ERA; INDIVIDUALS; ADOLESCENTS;
D O I
10.1371/journal.pone.0156523
中图分类号
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号
07 ; 0710 ; 09 ;
摘要
Objectives Definition of the optimal pneumococcal vaccine strategy in HIV-infected adults is still under evaluation. We aimed to compare immunogenicity and safety of the 13-valent pneumococcal conjugate vaccine (PCV13) versus the 23-valent polysaccharide vaccine (PPSV23) in HIV-infected adults. Methods We performed a pilot, prospective controlled study enrolling HIV-infected pneumococcal vaccine-naive outpatients, aged 18-65 years with CD4 counts >= 200 cells/mu L. Eligible subjects were recruited into two parallel groups: group 1 (n = 50) received two doses of PCV13 eight weeks apart, and group 2 (n = 50) received one dose of PPSV23, as part of their standard of care. Anti-pneumococcal capsular polysaccharide immunoglobulin G concentrations were quantified by ELISA at baseline, 8, 24 and 48 weeks. Clinical and viroimmunological follow-up was performed at the same time points. Unvaccinated, age-atched HIV-negative adults (n = 100) were also enrolled as baseline controls. Results Pre-vaccination specific IgG titers for each pneumococcal antigen did not differ between study groups but they were constantly lower than those from the HIV-negative controls. After immunization, significant increases in IgG titers were observed in both study groups at each time point compared to baseline, but response to serotype 3 was blunted in group 1. Antibody titers for each antigen did not differ between study groups at week 48. Overall, the proportion of subjects achieving seroprotection and seroconversion to all serotypes was comparable between groups. A marked decrease in IgG levels over time was observed with both vaccines. No relevant adverse reactions were reported in either group. Conclusions In this population with favorable immune profile, no relevant differences were observed in immunogenicity between PCV13 and PPSV23. Both vaccines were safe and well tolerated.
引用
收藏
页数:18
相关论文
共 38 条
[1]   Immunogenicity, safety, and predictors of response after a pneumococcal conjugate and pneumococcal polysaccharide vaccine series in human immunodeficiency virus-infected children receiving highly active antiretroviral therapy [J].
Abzug, Mark J. ;
Pelton, Stephen I. ;
Song, Lin-Ye ;
Fenton, Terence ;
Levin, Myron J. ;
Nachman, Sharon A. ;
Borkowsky, William ;
Rosenblatt, Howard M. ;
Marcinak, John F. ;
Dieudonne, Arry ;
Abrams, Elaine J. ;
Pathak, Indu .
PEDIATRIC INFECTIOUS DISEASE JOURNAL, 2006, 25 (10) :920-929
[2]   Effect of human immunodeficiency virus type 1 infection on the antibody response to a glycoprotein conjugate pneumococcal vaccine: Results from a randomized trial [J].
Ahmed, F ;
Steinhoff, MC ;
RodriguezBarradas, MC ;
Hamilton, RG ;
Musher, DM ;
Nelson, KE .
JOURNAL OF INFECTIOUS DISEASES, 1996, 173 (01) :83-90
[3]   Serotype-specific effectiveness and correlates of protection for the 13-valent pneumococcal conjugate vaccine: a postlicensure indirect cohort study [J].
Andrews, Nick J. ;
Waight, Pauline A. ;
Burbidge, Polly ;
Pearce, Emma ;
Roalfe, Lucy ;
Zancolli, Marta ;
Slack, Mary ;
Ladhani, Shamez N. ;
Miller, Elizabeth ;
Goldblatt, David .
LANCET INFECTIOUS DISEASES, 2014, 14 (09) :839-846
[4]  
[Anonymous], 2014, CADTH Rapid Response Reports. Emergency Medical Service Treat and Release Protocols: A Review of Clinical and Cost-Effectiveness, Safety
[5]  
[Anonymous], 2005, WHO TECHN REP SER
[6]   Serological response to 13-valent pneumococcal conjugate vaccine in children and adolescents with perinatally acquired HIV infection [J].
Bamford, Alasdair ;
Kelleher, Peter ;
Lyall, Hermione ;
Haston, Mitch ;
Zancolli, Marta ;
Goldblatt, David ;
Kampmann, Beate .
AIDS, 2014, 28 (14) :2033-2043
[7]  
Belmonti Simone, 2016, J Immunoassay Immunochem, V37, P189, DOI 10.1080/15321819.2015.1106949
[8]   Immunogenicity and safety of the 13-valent pneumococcal conjugate vaccine in HIV-infected individuals naive to pneumococcal vaccination [J].
Bhorat, As'ad E. ;
Madhi, Shabir A. ;
Laudat, France ;
Sundaraiyer, Vani ;
Gurtman, Alejandra ;
Jansen, Kathrin U. ;
Scott, Daniel A. ;
Emini, Emilio A. ;
Gruber, William C. ;
Schmoele-Thoma, Beate .
AIDS, 2015, 29 (11) :1345-1354
[9]  
*CDC, 1989, MMWR-MORBID MORTAL W, V38, P64
[10]   Pneumococcal Conjugate and Plain Polysaccharide Vaccines Have Divergent Effects on Antigen-Specific B Cells [J].
Clutterbuck, Elizabeth A. ;
Lazarus, Rajeka ;
Yu, Ly-Mee ;
Bowman, Jaclyn ;
Bateman, Elizabeth A. L. ;
Diggle, Linda ;
Angus, Brian ;
Peto, Tim E. ;
Beverley, Peter C. ;
Mant, David ;
Pollard, Andrew J. .
JOURNAL OF INFECTIOUS DISEASES, 2012, 205 (09) :1408-1416